Lou Junyao, Huang Xiufeng, Zhang Lifeng, Xu Ping, Zhang Xinmei, Chen Zhengyun
Department of Gynecology, the Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019 Apr 25;48(2):136-141. doi: 10.3785/j.issn.1008-9292.2019.04.03.
To determine the efficacy of second generation endometrial ablation (NovaSure) combined with levonorgestrel-releasing intrauterine system (Mirena) in the treatment of adenomyosis.
Clinical data of patients with adenomyosis admitted in Women's Hospital, Zhejiang University School of Medicine from January 2015 to December 2018 were retrospectively analyzed. Among 66 patients, 44 received Mirena placement only (control group) and 22 received Mirena placement and NovaSure treatment (study group). The menstruation blood loss, dysmenorrhea score, uterine size, expulsion rate of Mirena and the patients' satisfaction rate were assessed in two groups.
There was a significant reduction in menstruation blood loss (<0.05) and significant improvement in dysmenorrhea (<0.05) after the treatment in both groups. The patients in study group had more marked improvement in menstruation blood loss than those in control group (<0.05). The patients' satisfaction was higher and the expulsion rate of Mirena was lower in study group than that in control group (all <0.05). The score of dysmenorrhea and the size of uterine had no significant difference between two groups (all >0.05).
NovaSure can improve the efficacy of Mirena in treatment of adenomyosis.
确定第二代子宫内膜切除术(NovaSure)联合左炔诺孕酮宫内节育系统(曼月乐)治疗子宫腺肌病的疗效。
回顾性分析2015年1月至2018年12月浙江大学医学院附属妇产科医院收治的子宫腺肌病患者的临床资料。66例患者中,44例仅接受曼月乐放置(对照组),22例接受曼月乐放置及NovaSure治疗(研究组)。评估两组患者的月经量、痛经评分、子宫大小、曼月乐的脱落率及患者满意度。
两组治疗后月经量均显著减少(<0.05),痛经均显著改善(<0.05)。研究组患者月经量的改善比对照组更明显(<0.05)。研究组患者的满意度更高,曼月乐的脱落率低于对照组(均<0.05)。两组痛经评分及子宫大小比较,差异均无统计学意义(均>0.05)。
NovaSure可提高曼月乐治疗子宫腺肌病的疗效。